Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC

Targeted Oncology
13 Aug, 2019 ,

Dr. Wakelee discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with EGFR-positive non—small cell lung cancer (NSCLC). The most promising data were demonstrated in phase III IMpower150 trial. Patients enrolled in the IMpower150 trial were treated with a 4-drug combination, including atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel. Patients with EGFR-positive NSCLC experienced an improvement in overall survival (OS) and progression-free survival (PFS) with the 4-drug regimen.